Q3 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
LeqvioⓇ - siRNA (regulation of LDL-C)
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Leqvio® - siRNA (regulation of LDL-C)
Abbreviations
Other
NCT05030428 VICTORION-2P (CKJX839B12302)
Indication
Secondary prevention of cardiovascular events in patients with elevated levels
of LDL-C
Indication
Phase
NCT05739383 VICTORION-1P (CKJX839D12302)
CVRR (Primary prevention)
Phase 3
Phase
Phase 3
Patients
14000
Patients
16500
Primary
Outcome
Measures
Target
Patients
Readout
2027
Milestone(s)
Publication
TBD
Arms
Intervention
1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse
Cardiovascular Events)
Arm 1: Experimental Inclisiran sodium, Subcutaneous injection
Arm 2: Placebo Comparator, Placebo Subcutaneous injection
Participants with established cardiovascular disease (CVD)
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Time to the first occurrence of 4P-MACE
4-Point-Major Adverse Cardiovascular Events (4P-MACE): composite of
cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke,
and urgent coronary revascularization
Arm 1 Experimental: Inclisiran Sodium 300mg, subcutaneous injection in
pre-filled syringe
Arm 2 Placebo
High-risk primary prevention patients
Readout
Milestone(s)
2029
Publication
TBD
49 Investor Relations | Q3 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation